Joshua Barocas
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Opioid-Related Disorders | 19 | 2021 | 290 | 8.770 |
Why?
| Substance Abuse, Intravenous | 10 | 2021 | 112 | 6.380 |
Why?
| Drug Overdose | 12 | 2021 | 250 | 4.440 |
Why?
| Homeless Persons | 7 | 2021 | 77 | 4.230 |
Why?
| Hepatitis C | 9 | 2022 | 213 | 3.930 |
Why?
| Endocarditis | 4 | 2022 | 35 | 3.560 |
Why?
| Pharmaceutical Preparations | 6 | 2021 | 171 | 2.750 |
Why?
| Hepatitis C, Chronic | 4 | 2021 | 148 | 2.480 |
Why?
| Epidemics | 3 | 2022 | 64 | 2.350 |
Why?
| Hepacivirus | 7 | 2021 | 218 | 1.910 |
Why?
| Endocarditis, Bacterial | 2 | 2022 | 33 | 1.850 |
Why?
| Analgesics, Opioid | 12 | 2022 | 688 | 1.690 |
Why?
| Soft Tissue Infections | 2 | 2021 | 43 | 1.660 |
Why?
| Buprenorphine, Naloxone Drug Combination | 2 | 2019 | 7 | 1.570 |
Why?
| Central Nervous System Stimulants | 2 | 2022 | 143 | 1.560 |
Why?
| Substance-Related Disorders | 7 | 2021 | 951 | 1.540 |
Why?
| HIV Infections | 9 | 2022 | 2487 | 1.540 |
Why?
| Anti-Infective Agents | 2 | 2022 | 234 | 1.460 |
Why?
| Drug Users | 2 | 2021 | 41 | 1.440 |
Why?
| Naloxone | 2 | 2021 | 111 | 1.400 |
Why?
| Cost-Benefit Analysis | 6 | 2022 | 537 | 1.340 |
Why?
| Buprenorphine | 4 | 2021 | 80 | 1.340 |
Why?
| Coronavirus Infections | 3 | 2020 | 339 | 1.270 |
Why?
| Pneumonia, Viral | 3 | 2020 | 354 | 1.260 |
Why?
| Patient Isolation | 2 | 2021 | 18 | 1.120 |
Why?
| Opiate Substitution Treatment | 3 | 2021 | 58 | 1.090 |
Why?
| Housing | 2 | 2021 | 111 | 1.050 |
Why?
| Substance Abuse Treatment Centers | 2 | 2020 | 48 | 1.040 |
Why?
| Health Personnel | 2 | 2020 | 485 | 1.020 |
Why?
| Humans | 60 | 2022 | 113846 | 1.000 |
Why?
| Narcotic Antagonists | 3 | 2021 | 135 | 0.980 |
Why?
| Mass Screening | 6 | 2020 | 1055 | 0.960 |
Why?
| Preventive Health Services | 2 | 2020 | 140 | 0.950 |
Why?
| Crisis Intervention | 1 | 2021 | 23 | 0.940 |
Why?
| Criminal Law | 1 | 2021 | 18 | 0.930 |
Why?
| Hospital Administration | 1 | 2021 | 26 | 0.930 |
Why?
| Massachusetts | 6 | 2022 | 121 | 0.930 |
Why?
| Referral and Consultation | 2 | 2021 | 635 | 0.930 |
Why?
| Convalescence | 1 | 2021 | 16 | 0.890 |
Why?
| Communicable Diseases | 2 | 2021 | 113 | 0.890 |
Why?
| Hospital Units | 1 | 2021 | 23 | 0.890 |
Why?
| Residential Treatment | 1 | 2020 | 32 | 0.860 |
Why?
| Health Communication | 1 | 2021 | 47 | 0.860 |
Why?
| Hospitalization | 6 | 2021 | 1678 | 0.850 |
Why?
| Prisoners | 1 | 2021 | 86 | 0.850 |
Why?
| Antiviral Agents | 4 | 2022 | 639 | 0.840 |
Why?
| Safety-net Providers | 1 | 2021 | 105 | 0.790 |
Why?
| Immunization Programs | 1 | 2020 | 189 | 0.750 |
Why?
| Needle-Exchange Programs | 2 | 2015 | 11 | 0.750 |
Why?
| Socioeconomic Factors | 2 | 2020 | 1211 | 0.720 |
Why?
| Adult | 23 | 2022 | 31979 | 0.710 |
Why?
| Social Determinants of Health | 1 | 2019 | 99 | 0.690 |
Why?
| Liver Cirrhosis | 1 | 2019 | 198 | 0.690 |
Why?
| Diagnostic Tests, Routine | 1 | 2018 | 94 | 0.680 |
Why?
| Delivery of Health Care | 2 | 2021 | 695 | 0.680 |
Why?
| Sustained Virologic Response | 1 | 2017 | 35 | 0.680 |
Why?
| Outpatients | 2 | 2020 | 236 | 0.670 |
Why?
| Decision Support Techniques | 1 | 2021 | 388 | 0.660 |
Why?
| Public Health | 1 | 2021 | 422 | 0.650 |
Why?
| Male | 28 | 2022 | 60993 | 0.630 |
Why?
| Delivery of Health Care, Integrated | 1 | 2019 | 232 | 0.630 |
Why?
| Zinc | 1 | 2019 | 280 | 0.630 |
Why?
| Emergency Medical Services | 1 | 2022 | 521 | 0.620 |
Why?
| Guidelines as Topic | 1 | 2017 | 286 | 0.600 |
Why?
| Criminals | 1 | 2015 | 23 | 0.590 |
Why?
| Monte Carlo Method | 3 | 2021 | 160 | 0.590 |
Why?
| Female | 27 | 2022 | 63035 | 0.590 |
Why?
| Blastomyces | 1 | 2014 | 6 | 0.570 |
Why?
| Blastomycosis | 1 | 2014 | 7 | 0.570 |
Why?
| Education | 1 | 2015 | 110 | 0.560 |
Why?
| Boston | 4 | 2021 | 69 | 0.550 |
Why?
| HIV Seropositivity | 1 | 2014 | 108 | 0.540 |
Why?
| Advance Directives | 1 | 2014 | 69 | 0.540 |
Why?
| Peritonitis | 1 | 2014 | 78 | 0.540 |
Why?
| Young Adult | 10 | 2021 | 10971 | 0.530 |
Why?
| Prevalence | 6 | 2020 | 2407 | 0.500 |
Why?
| United States | 9 | 2022 | 12329 | 0.500 |
Why?
| Alcohol Drinking | 1 | 2019 | 721 | 0.490 |
Why?
| Pandemics | 6 | 2021 | 881 | 0.480 |
Why?
| Middle Aged | 14 | 2021 | 28753 | 0.450 |
Why?
| Quarantine | 2 | 2021 | 19 | 0.440 |
Why?
| Injections | 2 | 2021 | 164 | 0.430 |
Why?
| Kidney Transplantation | 1 | 2014 | 382 | 0.410 |
Why?
| Vulnerable Populations | 2 | 2021 | 127 | 0.400 |
Why?
| Retrospective Studies | 7 | 2021 | 11340 | 0.400 |
Why?
| Adolescent | 10 | 2021 | 18736 | 0.390 |
Why?
| Coinfection | 2 | 2019 | 109 | 0.370 |
Why?
| Health Services Accessibility | 3 | 2022 | 777 | 0.370 |
Why?
| Harm Reduction | 2 | 2020 | 28 | 0.360 |
Why?
| Risk-Taking | 2 | 2021 | 365 | 0.360 |
Why?
| Wisconsin | 3 | 2014 | 82 | 0.310 |
Why?
| Cohort Studies | 4 | 2021 | 5011 | 0.310 |
Why?
| Risk Factors | 4 | 2021 | 9050 | 0.290 |
Why?
| African Americans | 1 | 2009 | 1101 | 0.250 |
Why?
| Colorectal Neoplasms | 1 | 2009 | 584 | 0.250 |
Why?
| Quality-Adjusted Life Years | 2 | 2020 | 114 | 0.240 |
Why?
| Immunogenicity, Vaccine | 1 | 2022 | 23 | 0.240 |
Why?
| Arkansas | 1 | 2021 | 15 | 0.240 |
Why?
| Patient Acceptance of Health Care | 2 | 2021 | 641 | 0.240 |
Why?
| Naltrexone | 2 | 2021 | 85 | 0.240 |
Why?
| Ambulances | 1 | 2022 | 44 | 0.240 |
Why?
| Models, Economic | 1 | 2021 | 51 | 0.230 |
Why?
| Needle Sharing | 1 | 2021 | 11 | 0.230 |
Why?
| Age Factors | 2 | 2020 | 3330 | 0.230 |
Why?
| Interrupted Time Series Analysis | 1 | 2021 | 32 | 0.220 |
Why?
| Markov Chains | 1 | 2021 | 127 | 0.220 |
Why?
| Prescriptions | 1 | 2021 | 46 | 0.220 |
Why?
| Costs and Cost Analysis | 1 | 2021 | 210 | 0.220 |
Why?
| Drug Resistance, Viral | 2 | 2022 | 103 | 0.220 |
Why?
| Health Policy | 2 | 2021 | 354 | 0.220 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 4275 | 0.220 |
Why?
| Health Services | 1 | 2021 | 101 | 0.220 |
Why?
| Drug Compounding | 1 | 2021 | 97 | 0.210 |
Why?
| Inpatients | 2 | 2020 | 335 | 0.210 |
Why?
| Social Isolation | 1 | 2020 | 61 | 0.210 |
Why?
| Patient Advocacy | 1 | 2020 | 68 | 0.210 |
Why?
| Prescription Drugs | 1 | 2021 | 110 | 0.210 |
Why?
| Aged | 6 | 2021 | 20109 | 0.210 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 60 | 0.210 |
Why?
| Betacoronavirus | 2 | 2020 | 265 | 0.210 |
Why?
| Demography | 1 | 2020 | 294 | 0.200 |
Why?
| Communicable Disease Control | 1 | 2020 | 65 | 0.200 |
Why?
| Russia | 1 | 2019 | 10 | 0.200 |
Why?
| Sex Factors | 2 | 2020 | 1997 | 0.200 |
Why?
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 20 | 0.200 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 99 | 0.200 |
Why?
| Public Health Administration | 1 | 2020 | 81 | 0.200 |
Why?
| Age Distribution | 2 | 2018 | 403 | 0.190 |
Why?
| Sex Distribution | 2 | 2018 | 395 | 0.190 |
Why?
| Needs Assessment | 1 | 2020 | 343 | 0.180 |
Why?
| Narcotics | 1 | 2018 | 62 | 0.180 |
Why?
| Urban Population | 1 | 2021 | 420 | 0.180 |
Why?
| Child | 5 | 2021 | 17711 | 0.180 |
Why?
| Uridine Monophosphate | 1 | 2017 | 16 | 0.170 |
Why?
| Mental Health Services | 1 | 2021 | 325 | 0.170 |
Why?
| Fluorenes | 1 | 2017 | 42 | 0.170 |
Why?
| Rural Population | 1 | 2021 | 481 | 0.170 |
Why?
| Proportional Hazards Models | 1 | 2020 | 1141 | 0.170 |
Why?
| Sofosbuvir | 1 | 2017 | 55 | 0.170 |
Why?
| Ribavirin | 1 | 2017 | 90 | 0.160 |
Why?
| Disease Management | 1 | 2021 | 606 | 0.160 |
Why?
| Computer Simulation | 1 | 2021 | 948 | 0.160 |
Why?
| Vaccination | 2 | 2020 | 962 | 0.160 |
Why?
| Benzimidazoles | 1 | 2017 | 147 | 0.160 |
Why?
| Recurrence | 1 | 2018 | 967 | 0.150 |
Why?
| Midwestern United States | 1 | 2015 | 36 | 0.150 |
Why?
| Physician-Patient Relations | 1 | 2020 | 528 | 0.150 |
Why?
| Obesity | 1 | 2009 | 2627 | 0.150 |
Why?
| Skin | 1 | 2020 | 702 | 0.150 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2020 | 1136 | 0.150 |
Why?
| Incidence | 2 | 2020 | 2470 | 0.150 |
Why?
| Multivariate Analysis | 1 | 2019 | 1599 | 0.140 |
Why?
| Viral Load | 1 | 2017 | 470 | 0.140 |
Why?
| Surveys and Questionnaires | 4 | 2015 | 4625 | 0.140 |
Why?
| Health Promotion | 1 | 2021 | 664 | 0.140 |
Why?
| Amphotericin B | 1 | 2014 | 42 | 0.140 |
Why?
| Drug Therapy, Combination | 1 | 2017 | 1004 | 0.130 |
Why?
| Epidemiologic Methods | 1 | 2014 | 78 | 0.130 |
Why?
| Antifungal Agents | 1 | 2014 | 136 | 0.130 |
Why?
| Primary Health Care | 2 | 2014 | 1508 | 0.130 |
Why?
| Severity of Illness Index | 2 | 2020 | 2828 | 0.130 |
Why?
| RNA, Viral | 1 | 2017 | 598 | 0.130 |
Why?
| Mental Disorders | 1 | 2021 | 928 | 0.130 |
Why?
| Social Stigma | 1 | 2014 | 74 | 0.130 |
Why?
| Quality of Life | 2 | 2019 | 2136 | 0.130 |
Why?
| Early Diagnosis | 1 | 2014 | 251 | 0.120 |
Why?
| Professional-Patient Relations | 1 | 2014 | 147 | 0.120 |
Why?
| Anti-Bacterial Agents | 1 | 2022 | 1331 | 0.120 |
Why?
| Physicians | 1 | 2020 | 711 | 0.120 |
Why?
| Advance Care Planning | 1 | 2014 | 179 | 0.110 |
Why?
| Internal Medicine | 1 | 2013 | 225 | 0.110 |
Why?
| Genotype | 1 | 2017 | 2074 | 0.110 |
Why?
| Physicians, Primary Care | 1 | 2014 | 246 | 0.110 |
Why?
| Fear | 1 | 2014 | 324 | 0.110 |
Why?
| Recreation Therapy | 1 | 2010 | 1 | 0.110 |
Why?
| Pregnancy, High-Risk | 1 | 2010 | 13 | 0.110 |
Why?
| Infant, Newborn | 1 | 2021 | 5080 | 0.100 |
Why?
| Bed Rest | 1 | 2010 | 25 | 0.100 |
Why?
| Music Therapy | 1 | 2010 | 19 | 0.100 |
Why?
| Decision Making | 1 | 2016 | 774 | 0.100 |
Why?
| Education, Medical, Graduate | 1 | 2013 | 385 | 0.100 |
Why?
| Chronic Disease | 1 | 2014 | 1681 | 0.090 |
Why?
| Internship and Residency | 2 | 2014 | 967 | 0.080 |
Why?
| Attitude of Health Personnel | 1 | 2014 | 997 | 0.080 |
Why?
| Cachexia | 1 | 2005 | 16 | 0.080 |
Why?
| Counseling | 1 | 2009 | 360 | 0.080 |
Why?
| Anorexia | 1 | 2005 | 22 | 0.080 |
Why?
| Recovery of Function | 1 | 2008 | 604 | 0.070 |
Why?
| Pregnancy Complications | 1 | 2010 | 483 | 0.070 |
Why?
| Patient Education as Topic | 1 | 2009 | 739 | 0.070 |
Why?
| Healthcare Disparities | 1 | 2009 | 465 | 0.070 |
Why?
| Neoplasms | 2 | 2008 | 2037 | 0.070 |
Why?
| Treatment Outcome | 1 | 2017 | 9002 | 0.060 |
Why?
| Immunization, Secondary | 1 | 2022 | 76 | 0.060 |
Why?
| Oregon | 1 | 2021 | 66 | 0.060 |
Why?
| Vaccines, Synthetic | 1 | 2022 | 93 | 0.060 |
Why?
| Public Health Practice | 1 | 2022 | 63 | 0.060 |
Why?
| British Columbia | 1 | 2020 | 11 | 0.060 |
Why?
| Infectious Disease Medicine | 1 | 2020 | 9 | 0.050 |
Why?
| Health Care Rationing | 1 | 2020 | 52 | 0.050 |
Why?
| Human Rights | 1 | 2020 | 17 | 0.050 |
Why?
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.050 |
Why?
| Federal Government | 1 | 2020 | 28 | 0.050 |
Why?
| Ohio | 1 | 2020 | 128 | 0.050 |
Why?
| Hepatitis B | 1 | 2020 | 42 | 0.050 |
Why?
| Stress, Psychological | 1 | 2010 | 1127 | 0.050 |
Why?
| New York | 1 | 2020 | 118 | 0.050 |
Why?
| Methadone | 1 | 2021 | 70 | 0.050 |
Why?
| Delayed-Action Preparations | 1 | 2021 | 173 | 0.050 |
Why?
| State Government | 1 | 2020 | 50 | 0.050 |
Why?
| Canada | 1 | 2021 | 336 | 0.050 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 1227 | 0.050 |
Why?
| Comparative Effectiveness Research | 1 | 2020 | 143 | 0.050 |
Why?
| North America | 1 | 2020 | 274 | 0.050 |
Why?
| Specialization | 1 | 2020 | 123 | 0.050 |
Why?
| Infection Control | 1 | 2020 | 135 | 0.050 |
Why?
| Evidence-Based Practice | 1 | 2020 | 166 | 0.050 |
Why?
| Bacteremia | 1 | 2020 | 164 | 0.050 |
Why?
| Regression Analysis | 1 | 2020 | 1137 | 0.040 |
Why?
| Patient Compliance | 1 | 2022 | 604 | 0.040 |
Why?
| Leadership | 1 | 2020 | 313 | 0.040 |
Why?
| Societies, Medical | 1 | 2020 | 768 | 0.040 |
Why?
| Databases, Factual | 1 | 2020 | 1206 | 0.040 |
Why?
| Antibodies, Monoclonal | 1 | 2022 | 1302 | 0.040 |
Why?
| Research Design | 1 | 2020 | 913 | 0.040 |
Why?
| Patient Readmission | 1 | 2020 | 621 | 0.030 |
Why?
| Patient Discharge | 1 | 2020 | 743 | 0.030 |
Why?
| Focus Groups | 1 | 2013 | 357 | 0.030 |
Why?
| Behavior Therapy | 1 | 2014 | 241 | 0.030 |
Why?
| Watchful Waiting | 1 | 2010 | 52 | 0.030 |
Why?
| Qualitative Research | 1 | 2013 | 781 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2005 | 64 | 0.020 |
Why?
| Psychometrics | 1 | 2005 | 671 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2008 | 2905 | 0.010 |
Why?
| Prospective Studies | 1 | 2010 | 6250 | 0.010 |
Why?
| Pregnancy | 1 | 2010 | 5290 | 0.010 |
Why?
| Prognosis | 1 | 2005 | 3544 | 0.010 |
Why?
| Risk Assessment | 1 | 2005 | 3147 | 0.010 |
Why?
|
|
Barocas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|